The “American Clinical Chemistry Analyzer Market by Product (Semi-Automated Clinical Chemistry and Fully-Automated Clinical Chemistry Analyzer), by End-User (Academic Research Institutes, Diagnostic Laboratories, Hospitals) - Forecast to 2019” is expected to reach a value of $1,496.4 Million by 2019, estimated to grow at a CAGR of 5.2% from 2014 to 2019.
Browse through the TOC of “American Clinical Chemistry Analyzer Market by Product (Semi-Automated Clinical Chemistry and Fully-Automated Clinical Chemistry Analyzer), by End-User (Academic Research Institutes, Diagnostic Laboratories, Hospitals) - Forecast to 2019” for an analysis of industry trends and segments, with the help of various tables and figures.
Early buyers will receive 10% customization on reports.
Clinical chemistry analyzers are the devices/instruments that read and analyze the fluid present in the human body. These fluids are considered to be one of the vital parts in a human body. The main function of the fluids is to connect plethora of cells to transport essential minerals such as vitamins and calcium in arteries and veins. The content of minerals in body fluids must be accurate in order to avoid diseases like hyponatremia.
The major drivers of clinical chemistry analyzers market in America are increasing healthcare expenditure, increasing ageing population & prevalence rate of lifestyle diseases, rise in rental agreements and increasing medical insurances.
The percentage of Americans aging 65 and older remains high, at 25.9%, and one adult in ten has diabetes in North America. New figures indicate that the number of people living with diabetes is expected to rise from 366 million in 2011 to 552 million by 2030. In the North American and Caribbean regions in 2011, an estimated 37.7 million people were living with diabetes and this is expected to increase enormously in the coming years. The U.S., with an estimated 23.7 million people, has the highest number of people with diabetes followed by Mexico, and Canada. In 2012, 29.1 million Americans, or 9.3% of the population, had suffered from diabetes.
In 2010, after adjusting for population age differences, hospitalization rates for heart attack were 1.8 times higher among adults aged 20 years or older with diagnosed diabetes, than among adults without diagnosed diabetes.
U.S. is the highest contributor to the Clinical Chemistry Analyzers market in America, as it accounted for 27.6% in 2014.
This market is segmented and forecast on the basis of different type, end-user, and technology. There are two major types of clinical chemistry analyzers, namely semi-automated and fully automated. Hospitals, Diagnostic Centers, and Academic Research Institutes are included in this market report on the basis of end-user. Further, the market is segmented and forecast on the basis of major countries, such as the U.S., Canada, Mexico, Chile, and Rest of Americas (RoA).
This report also includes the market share, market metrics such as drivers, restraints and also the upcoming opportunities in the market. In addition, it presents a competitive landscape and company profiles of the key players in the market.
About MicroMarket Monitor:
MicroMarket Monitor identifies and attends to various unmet needs of different industrial verticals, which include value chain impact analysis. The company publishes about 12000 Market Research Reports on various Micro Markets across the world. The graphical nature and multidimensional analysis of these reports provide advanced Business Intelligence Tools to the clients in that particular target market.
Contact:
Mr. Chandrasekhar K.
UNIT no 802, Tower No. 7, SEZ
Magarpatta City, Hadapsar
Pune, Maharashtra 411013,
India
Tel: +1-888-502-0539
Email: sales@micromarketmonitor.com
